Immunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are presently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $7.50.

A number of research analysts recently commented on the company. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Immunic in a research note on Wednesday, June 25th. B. Riley restated a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a research report on Friday, May 23rd. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. Finally, William Blair restated an "outperform" rating on shares of Immunic in a research note on Friday, May 16th.

Hedge Funds Weigh In On Immunic

A number of institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC raised its position in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after buying an additional 479,846 shares during the last quarter. Renaissance Technologies LLC grew its position in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after purchasing an additional 177,542 shares in the last quarter. Barclays PLC bought a new position in shares of Immunic during the 4th quarter worth approximately $84,000. Invesco Ltd. purchased a new position in shares of Immunic in the 4th quarter worth approximately $37,000. Finally, Focus Partners Wealth increased its position in shares of Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock valued at $2,168,000 after acquiring an additional 23,610 shares during the last quarter. 51.82% of the stock is currently owned by institutional investors.

Immunic Price Performance

Immunic stock traded down $0.01 during trading hours on Thursday, hitting $0.93. The company had a trading volume of 668,229 shares, compared to its average volume of 1,065,974. The firm has a 50-day moving average of $0.83 and a 200 day moving average of $0.97. The firm has a market cap of $89.26 million, a PE ratio of -0.76 and a beta of 1.38. Immunic has a one year low of $0.56 and a one year high of $2.11.

Immunic (NASDAQ:IMUX - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) EPS for the quarter, hitting analysts' consensus estimates of ($0.25). As a group, research analysts expect that Immunic will post -0.94 earnings per share for the current year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.